Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing precision medicines for serious unmet medical needs in oncology. Its pipeline centers on drug candidates NXP800 and NXP900, which are being advanced through early clinical development from the company’s operations in the United States.

2.38

2.38

— Nuvectis Pharma, Inc.
%
NXP90050% A small-molecule oncology candidate targeting SRC/YES1 kinases in precision medicine applications.
NXP80050% A precision oncology drug candidate being developed for serious cancers with unmet medical need.
Drug discovery and in-licensing0% Acquisition and licensing of product candidates and related intellectual property rights.
Preclinical and clinical development0% IND-enabling studies, Phase 1 trials, and supporting development activities for pipeline assets.

Nuvectis does not yet sell commercial products; its current work is directed toward regulators, clinical investigators,...

  • Regulatory agenciesprimary

    FDA, MHRA, and other authorities review INDs and clinical trial applications needed to advance NXP800 and NXP900.

  • Clinical trial sites and investigatorsprimary

    Hospitals, research centers, and investigators conduct early-phase studies and enroll patients for the pipeline.

  • Future commercialization partnerssecondary

    Potential third-party collaborators that could market, sell, or distribute approved products.

  • Oncology patients and physiciansemerging

    The eventual end market for approved precision medicines targeting serious cancers.

Nuvectis is headquartered in Fort Lee, New Jersey and operates as a U.S.-based development company...

  • •Headquartered in Fort Lee, New Jersey, United States
  • •Core operations are managed from the U.S. as a Delaware corporation
  • •Clinical trial activity has included the United Kingdom and Spain
  • •Regulatory filings with the FDA are central to both programs
  • •No revenue by country disclosed because the company has not generated revenue

The company’s strategy is to advance NXP800 and NXP900 through early clinical development and generate value through...

01
Progress NXP800 and NXP900 through clinical developmentshort-term

Early human data is the main value-creation step for a clinical-stage biotech.

02
Secure financing to support pipeline executionshort-term

The company has no product revenue and depends on external capital to fund trials.

03
Build regulatory and scientific evidence for precision oncology assetsmedium-term

Clinical and regulatory validation improves partnering and approval prospects.

Nuvectis faces the classic risks of an early-stage biotech: clinical failure, regulatory setbacks, and dependence on...

critical

Clinical development failure

Both NXP800 and NXP900 are in early-stage trials, so efficacy or safety issues could halt development.

Scope
NXP800 and NXP900 pipeline
Materiality
high
high

Financing and liquidity dependence

The company has no product sales and relies on external capital to fund operations and trials.

Scope
Operating runway and trial funding
Materiality
high
high

Regulatory approval risk

INDs, CTAs, and eventual marketing approvals may be delayed or denied by regulators.

Scope
FDA, MHRA, Spanish regulators
Materiality
high
medium

Commercialization and partner execution risk

The company has no sales and marketing organization and may need third-party collaborators.

Scope
Future launch and distribution
Materiality
medium
medium

Cybersecurity and data integrity

Clinical and proprietary data are sensitive, and breaches or data loss could delay development.

Scope
Clinical trial data and IP
Materiality
medium
Research and development expense recognition
Trial timing can materially change quarterly operating results
Share-based compensation
Can materially affect operating expenses and non-cash charges
License and milestone obligations
Can create lumpy expense recognition and cash outflows
Emerging growth company accounting
May affect timing and comparability of reported results

Nuwellis, Inc.

NUWE · Electromedical & Electrotherapeutic Apparatus

Nuvalent, Inc.

NUVL · Pharmaceutical Preparations

Xeris Biopharma Holdings, Inc.

XERS · Pharmaceutical Preparations

Nuvation Bio Inc.

NUVB · Pharmaceutical Preparations

SOLIGENIX, INC.

SNGX · Pharmaceutical Preparations

CalciMedica, Inc.

CALC · Pharmaceutical Preparations

: 29.4.2026